David Wallace/LinkedIn
Sep 3, 2026, 00:52
David Wallace: FDA Approves MIMRYLO to Target Iron Regulation and Reduce Phlebotomy Burden
David Wallace, Executive Director at MPN Cancer Connection, shared a post on LinkedIn:
“A major milestone in polycythemia vera treatment.
The FDA has approved MIMRYLO (rusfertide), a first-in-class hepcidin mimetic for erythrocytosis in adults with PV.
PV Reporter examines the clinical results, potential impact on phlebotomy burden, and questions patients may want to discuss with their hematologists.”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 00:44Same goal, Different molecular strategy – Which FVIIIa Mimetic Gets There How? – RPTH Journal
-
Sep 3, 2026, 00:33Hannah Isles: Interesting Link between Aging, Serotonin, Platelets and COVID-19 Severity
-
Sep 3, 2026, 00:22Danny Hsu: Paradigm Shift in PE Management? – Unpacking the PRAGUE-26 Trial
-
Sep 3, 2026, 00:14Leonardo Roever: Antiphospholipid Antibodies Present in 19% of Ischemic Stroke Cases
-
Sep 3, 2026, 00:03Jochebed Adwoa Sutherland: First Reported Case of Breast Mondor’s Disease in a Patient Living with Sickle Cell
-
Sep 2, 2026, 23:50Shashank Joshi: Individualized vs. Standard BP Control Shows Similar 90-Day Outcomes
-
Sep 2, 2026, 18:26Strengthening Comprehensive Care for Inherited Bleeding Disorders in Ecuador – World Federation of Hemophilia
-
Sep 2, 2026, 18:24Zeeshan Ahmed Khattak: Managing Febrile Neutropenia in Hematology/Oncology and Transplant Patients
-
Sep 2, 2026, 18:22Mark Heyland: The Role of Thromboinflammation in Fracture Non-Union